Oct 25 (CIDRAP News) Two studies published online by Nature this week help explain how anthrax toxin works, possibly paving the way for the development of drugs that could block the toxin's action. One group of researchers explains how it identified the cell-surface receptor that enables anthrax toxin to invade host cells, while another group describes the precise molecular structure of a key component of the toxin.
Nov 29, 2001 (CIDRAP News) The US Department of Health and Human Services (HHS) has awarded Acambis Inc. a $428 million contract to produce an additional 155 million doses of smallpox vaccine by the end of 2002, HHS Secretary Tommy G. Thompson announced Wednesday.
(CIDRAP News) – Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) have determined that a single injection of a fast-acting experimental Ebola vaccine confers protection against the disease in monkeys after just 1 month.
(CIDRAP News) Federal health officials yesterday announced grants to build 11 new biodefense laboratories around the country, including two that will be authorized to study the most dangerous pathogens.
(CIDRAP News) – The British biotechnology company Acambis announced yesterday that it has launched the first clinical trial of its vaccine for West Nile virus, called ChimeriVax-West Nile.
The phase 1 trial will involve 60 adult volunteers in Lenexa, Kan., the company said in a news release. The volunteers will receive one of three doses of the West Nile vaccine or a licensed yellow fever vaccine that is being used as a control.
(CIDRAP News) Albany Medical College in Albany, N.Y., has received an $8.3 million federal grant to study pulmonary tularemia, with the main emphasis on developing a vaccine, college officials announced last week.
The grant from the National Institute of Allergy and Infectious Diseases (NIAID) will fund tularemia research at the college for 4½ years, the college said in a news release.
(CIDRAP News) A test of smallpox vaccine made by Aventis Pasteur in the 1950s show it is still effective even when diluted, suggesting that the United States has more than enough vaccine for everyone, according to a report this week in the Journal of the American Medical Association.
(CIDRAP News) In a bid to limit the threat of an influenza pandemic, the Department of Health and Human Services (HHS) is awarding a contract to Aventis Pasteur Inc. to make 2 million doses of a vaccine for humans to protect against H5N1 avian influenza.